NeoGenomics launches blood-based cancer test PanTracer LBx

NeoGenomics Inc. (NASDAQ: NEO) announced the launch of PanTracer LBx, a blood-based comprehensive genomic profiling test for patients with advanced solid tumors when tissue samples are limited or unavailable.

The test uses circulating tumor DNA from blood draws to analyze over 500 genes, including microsatellite instability and blood-based tumor mutational burden. PanTracer LBx offers a seven-day turnaround time and can be ordered as a standalone test, as a reflex when tissue testing fails, or alongside tissue analysis.

"The launch of our liquid biopsy test positions us at the forefront of the precision oncology market," said Tony Zook, Chief Executive Officer of NeoGenomics. "As demand grows for faster, less invasive, and more accessible genomic testing, PanTracer LBx expands our addressable market, enhances our clinical portfolio, and opens new revenue streams."

The test supports therapy selection, clinical trial matching, and longitudinal disease monitoring. It complements the company's existing tissue-based PanTracer Tissue test, expanding NeoGenomics' comprehensive genomic profiling portfolio for solid tumors.

NeoGenomics stated the launch positions the company in the liquid biopsy market, which it estimates at $3-5 billion. The Fort Myers, Florida-based company operates laboratories in the United States and the United Kingdom, providing cancer diagnostic services to oncologists, pathologists, hospital systems, academic centers, and pharmaceutical companies.

The information is based on a company press release.

You May Also Be Interested In

• SpaceX files for 555.56M share IPO at $135/sh
• 3 E Network Technology (MASK) files for 17.13M share offering by selling stockholders
• American Resources receives Nasdaq notice for late 10-Q filing